1. 标的：VLA EU Valneva
2. 分类：讨论
3. 分析/正文：
以下资料来源：
official EU website
https://i.imgur.com/tPFkGG0.jpg
欧盟官方网站
COVID-19 Vaccine (inactivated, adjuvanted) Valneva is now authorised across the
EU.
COVID-19 疫苗（灭活、佐剂）Valneva 现在已在整个欧盟获得授权。
After a thorough evaluation, EMA’s human medicines committee (CHMP) concluded b
y consensus that the data on the vaccine were robust and met the EU criteria for
efficacy, safety and quality.
The main study conducted with Valneva’s vaccine is an immunobridging trial. Imm
unobridging trials compare the immune response induced by a new vaccine with tha
t induced by an authorised comparator vaccine proven to be effective against the
disease.
Results from the study, which involved nearly 3,000 people aged 30 years and old
er, showed that the vaccine triggers the production of higher levels of antibodi
es against the original strain of SARS-CoV-2 than the comparator, Vaxzevria. In
addition, the proportion of people who produced a high level of antibodies was s
imilar for both vaccines.
经过全面评估后，EMA 的人用药物委员会 (CHMP) 一致认为疫苗的数据是可靠的，并且符合
欧盟的有效性、安全性和品质标准。
使用 Valneva 疫苗进行的主要研究是免疫桥接试验。 免疫桥接试验将新疫苗诱导的免疫
反应与经授权的对照疫苗诱导的免疫反应进行比较，这些疫苗已被证明对疾病有效。
该研究涉及近 3,000 名 30 岁及以上的人，结果表明，与对照疫苗 Vaxzevria 相比，该
疫苗引发的针对 SARS-CoV-2 原始毒株的抗体水平更高。 此外，两种疫苗产生高水平抗体
的比例相似。
以上资料来源：
official EU website欧盟官方网站
欧盟包含德国法国，比利时，荷兰..等国家
现在大部分国家已经大幅放宽防疫限制了，确诊武汉肺炎的数量已经不太重要，大部分是轻
症小感冒
不过因为传染力太强基数太高，死亡人数还是有https://i.imgur.com/q8APqw7.jpg
https://i.imgur.com/vC6CQVs.jpg
股价
https://i.imgur.com/dmIR4ld.jpg
https://i.imgur.com/o73EnNk.jpg